Table 1 Demographic and clinical characteristics
From: Effect of spectral CT on tumor microvascular angiogenesis in renal cell carcinoma
Variable | Patients (n = 32) |
|---|---|
Age (years) | 53.53 ± 8.15 |
Male/Female | 25 (78.1%)/7 (21.9%) |
MWC/MNWC (mg/ml) | |
Renal cortical phase | 95.61 ± 33.89/0.42 (0.31–0.47) |
Renal parenchymal phase | 82.74 ± 20.54/0.39 ± 0.15 |
Renal excretory phase | 65.37 ± 12.21/0.78 ± 0.17 |
RWC/RNWC (mg/ml) | |
Renal cortical phase | 95.53 ± 44.48/0.39 ± 0.23 |
Renal parenchymal phase | 85.06 ± 23.07/0.73 ± 0.21 |
Renal excretory phase | 65.26 ± 14.14/0.75 ± 0.18 |
MIC/MNIC (mg/ml) | |
Renal cortical phase | 28.99 ± 14.52/0.33 ± 0.14 |
Renal parenchymal phase | 24.65 ± 8.37/0.71 ± 0.23 |
Renal excretory phase | 17.09 ± 6.60/0.91 (0.78–1.05) |
RIC/RNIC (mg/ml) | |
Renal cortical phase | 27.00 (19.50–34.25)/ 0.32 ± 0.16 |
Renal parenchymal phase | 24.16 ± 8.86/0.70 ± 0.27 |
Renal excretory phase | 16.95 ± 5.49/0.79 ± 0.27 |
WCD1/NWCD1 (mg/ml) | 12.87 ± 21.26/−0.30 ± 0.13 |
WCD2/NWCD2 (mg/ml) | 30.24 ± 27.82/− 0.40[− 0.46-(− 0.30)] |
WCD3/NWCD3 (mg/ml) | 17.37 ± 13.38/− 0.12(− 0.22–0.02) |
ICD1/NICD1 (mg/ml) | 4.14(−2.91–8.17)/ -0.388 ± 0.15 |
ICD2/NICD2 (mg/ml) | 13.17 (2.18–16.34)/ -0.56[− 0.75-(− 0.42)] |
ICD3/NICD3 (mg/ml) | 7.56 ± 4.92/− 0.21[− 0.36-(− 0.05)] |
Microvascular grading | |
II | 15 (46.9%) |
III | 17 (53.1%) |
MVD | 26.00 (15.00–43.75) |
MVA(%) | 16.16 ± 8.98 |
Microvascular diameter (μm) | 20.63 ± 9.73 |
Diameter of analyzed tumor tissue (μm) | 55.19 ± 19.15 |
Microvascular diameter/ Tumor diameter (%) | 40.98 ± 19.66 |